senores Pharmaceuticals: Shielded from US Tariffs, Positioned for Growth
Table of Contents
The US government recently announced a 100 percent tariff on branded and patented drug imports effective October 1. This decision sparked concerns among investors, as companies relying heavily on US exports could face a critically important impact.
Though, firms with domestic manufacturing in the US are largely exempt from this tariff, mitigating the potential downside. Senores Pharmaceuticals stands out in this scenario,with an established US facility ensuring tariff immunity and continuity of operations.
About the Company
Senores Pharmaceuticals Limited, together with its subsidiaries, is a research-driven global pharmaceutical company focused on developing and manufacturing a wide range of products for the US, Canada, and other regulated and emerging markets.
the company’s current portfolio includes 70 ANDA and 27 CMO/CDMO commercial products approved for distribution in the US. Senores also manufactures complex generics certified by global authorities and serves more than 40 emerging markets with over 308 product registrations and 719 applications.
The company operates two formulation manufacturing facilities-one in Atlanta, US, USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies, and the other in chhatral, Ahmedabad, India, WHO-GMP approved for emerging markets. In addition, Senores runs two API manufacturing sites in India (Chhatral and Naroda) and has strong R&D capabilities across three sites (one in the US, two in india).
Senores Pharmaceuticals currently has a market capitalization of Rs. 3,373.43 crore and a stock price of Rs. 732.50, delivering a return of 32.56 percent over the past six months.
Regulated Markets Business
Senores primarily serves the US, Canada, and the United Kingdom, contributing 65 percent of total revenue in Q1FY26. The company’s USFDA-approved Atlanta facility supports both its own products and CDMO/CMO operations. The regulated markets portfolio comprises 24 commercialized products, 70 approved ANDA products, 57 pipeline products, and 37 pipeline CGT prospect products.
Mr. Swapnil Shah, Managing Director, said, “Our moat lies in our ability to serve the government channel along with the retail channel in the US. this gives us considerable competitive advantage in the US market. A large part of our product pipeline has potential to cater to government contracts. Our capability to manufacture and supply controlled substances in the US is another differentiator for us.
Our CDMO/CMO segment is also scaling up as planned. We are adding new contracts and increasing the share of pocket from existing customers. The contracts in hand give us good visibility for the year ahead. With respect to the US tariff situation,we believe we are largely insulated with our entire formulation manufacturing happening locally in the US.”
CDMO/CMO Operations In Regulated Markets
The company offers customized formulation, growth,